US20020031819A1 - Screening process for antibacterial agents - Google Patents

Screening process for antibacterial agents Download PDF

Info

Publication number
US20020031819A1
US20020031819A1 US09/842,637 US84263701A US2002031819A1 US 20020031819 A1 US20020031819 A1 US 20020031819A1 US 84263701 A US84263701 A US 84263701A US 2002031819 A1 US2002031819 A1 US 2002031819A1
Authority
US
United States
Prior art keywords
bacteria
antibacterial
stationary phase
agent
phenotypically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/842,637
Other languages
English (en)
Inventor
Anthony Coates
Yanmin Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helperby Therapeutics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824553.3A external-priority patent/GB9824553D0/en
Priority claimed from GBGB9909962.4A external-priority patent/GB9909962D0/en
Application filed by Individual filed Critical Individual
Priority to US09/842,637 priority Critical patent/US20020031819A1/en
Assigned to ST. GEORGES'S ENTERPRISES LIMITED reassignment ST. GEORGES'S ENTERPRISES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COATES, ANTHONY R.M., HU, YANMIN
Publication of US20020031819A1 publication Critical patent/US20020031819A1/en
Assigned to HELPERBY THERAPEUTICS LIMITED reassignment HELPERBY THERAPEUTICS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ST.GEORGES'S ENTERPRISES LTD.
Priority to US10/919,354 priority patent/US20050019892A1/en
Priority to US12/343,176 priority patent/US7892782B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to the isolation of subpopulations of stationary phase bacteria which exhibit resistance to conventional antibacterial agents, to the use of such resistant subpopulations in screening processes for the identification of new and improved antibacterial agents, to novel antibacterial agents identified thereby, and to therapeutic applications of such antibacterials.
  • Tuberculosis remains a serious disease throughout the world and it has been estimated that deaths resulting from tuberculosis account for 7% of the total number of deaths from infectious diseases.
  • U.S. Pat. No. 5,700,925 the vast majority of individuals who become infected with Mycobacterium tuberculosis do not develop symptomatic tuberculosis but do exhibit a positive reaction to the tuberculin skin test. In such infected hosts, some bacteria persist in a dormant or latent state in which they are substantially resistant to antimicrobial drugs.
  • M. tuberculosis in an in vitro stationary phase model obtained by long term culturing of the organisms in a microaerophilic gradient in which the stationary phase organisms are viable.
  • stationary phase bacteria were found to be resistant to rifampicin at the normal minimum inhibitory concentration (MIC) level of 0.1 ⁇ g/ml (as assessed with bacteria at concentration of 10 6 -10 7 cfu/ml). Viability of M.
  • tuberculosis in vivo before and after treatment with anti-tuberculosis agents has also been examined.
  • Viable persistent non-culturable bacteria were present after treatment with antibacterials, whose dormancy was reversed when the host animals were subjected to steroid therapy.
  • the present invention is based on the unexpected and surprising finding that, whilst treatment of such stationary phase bacteria with antibacterial agents such as rifampicin at concentrations greatly exceeding the minimum inhibitory concentration reduces plate counts to zero colony forming units (CFU's), there remains a small number of persistent organisms which are detectable by, for example, broth dilution counting. These resistant subpopulations are phenotypically resistant to rifampicin, since they become sensitive to rifampicin at normal MIC levels upon resumption of growth.
  • the present invention thus provides a method of preparing a phenotypically antibiotic-resistant subpopulation of stationary phase bacteria comprising at least the steps of:
  • the “phenotypically antibiotic-resistant” bacteria refers to a portion of the stationary phase bacteria which remain metabolically active (e.g. as examined by transcriptional activity) after treatment of the stationary phase bacteria with a particular antibiotic (or more than one antibiotic) administered at a high dosage, namely at least 10 times higher than MIC.
  • This subpopulation is however susceptible to treatment with the antibiotic when not in the stationary phase. It will be appreciated that a subpopulation of bacteria resistant to a particular antibiotic may be distinct to a subpopulation resistant to a different antibiotic.
  • antibiotic refers to a loss of viability as assessed by a lack of metabolic activity.
  • antibiotic is administered to the stationary phase for an appropriate time and at an appropriate concentration.
  • antibiotic is applied at a concentration of from 10 to 10 4 ⁇ MIC, e.g. at a concentration of 25 to 150 ⁇ g/ml (e.g. 50 to 100 ⁇ g/ml) with the bacteria at a concentration of 10 5 to 10 9 bacteria/ml (e.g. 10 6 to 10 7 bacterial/ml).
  • bacteria are treated with the anti-bacterial agent(s) for 1-10 days, e.g. 3-5 days.
  • antibacterial agent employed may depend on the particular bacteria being investigated.
  • antibacterial agents such as rifampicin which target RNA polymerase, for example at concentrations of 10 2 , 10 3 or 10 4 times the normal MIC level
  • treatment of stationary phase M. tuberculosis at a level of 10 6 bacteria/ml for one day with 100 ⁇ g/ml of rifampicin (MIC ⁇ 10 3 ) resulted in a phenotypically resistant subpopulation of 10 2 bacteria/ml.
  • M. tuberculosis may be treated with pyrazinamide.
  • treatment of stationary phase E. coli or S. aureus ( ⁇ 10 9 bacteria/ml) with 50 ⁇ g/ml kanamycin or 100 ⁇ g/ml ampicillin for 3 days results in a phenotypically resistant subpopulation of ⁇ 10 5 bacteria/ml.
  • the phenotypically antibiotic-resistant subpopulation may be seen as representative of the persistent bacteria which remain metabolically active in vivo and which can result in relapse or onset of disease.
  • antibiotic-resistant populations from bacteria which exhibit dormancy in vivo, e.g. bacteria from the genera Staphylococcus, Escherichia, Hemophilus and Mycobacterium.
  • Particularly preferred are subpopulations from the bacteria Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Streptococcus pyogenes, Streptococcus gordonii and Mycobacterium tuberculosis.
  • the bacteria are Mycobacterium tuberculosis, Escherichia coli and Staphylococcus aureus treated with rifampicin, kanamycin and ampicillin, respectively.
  • Such phenotypically resistant subpopulations of stationary phase bacteria obtainable by treating stationary phase bacteria with a high dosage of an antibacterial agent, constitute a further feature of the present invention.
  • the phenotypically resistant subpopulations of the invention mimic the behaviour of dormant bacteria in vivo, they constitute valuable tools in screening procedures designed to identify potentially valuable new antibacterial agents. It will be appreciated that antibacterial agents having activity against such phenotypically resistant subpopulations may have great therapeutic potential in the treatment of diseases such as tuberculosis in which dormant bacteria provide a pool for reinfection.
  • the present invention provides a process for assessing the antibacterial activity of a test compound or agent or for identifying or isolating a compound or agent having antibacterial activity against stationary phase bacteria comprising the steps of:
  • the compounds to be screened may be any chemical compounds and may be already known or may themselves be novel.
  • Especially suitable candidate compounds are the products of combinatorial chemistry, phage display libraries, natural products, synthetic, semi-synthetic or natural homologues, analogues, derivatives and precursors of known antimicrobial agents or other pharmaceuticals.
  • homologues, analogues, derivatives and precursors are entities which are related to or derived from naturally occurring antimicrobials or other pharmaceuticals, e.g.
  • this is a protein or peptide by single or multiple amino acid substitution, addition and/or deletion or alteration of the level of glycosylation, or if the antimicrobial is a chemical compound by chemical derivatization, e.g. esterification, addition of various substituents, methylation etc.
  • the above described modifications will not affect the principal function of the molecule, e.g. they will retain antimicrobial activity although the extent of this activity may be modified.
  • assessing includes both quantitation in the sense of obtaining an absolute value of the extent of anti-bacterial activity, and also obtaining a semi-quantitative assessment or other indication, e.g. an index or ratio, of the amount of anti-bacterial activity in the sample. Assessing includes the identification of both positive effects on bacterial activity. The identification and optional isolation of agents or compounds which exhibit anti-bacterial effects is however preferred. Such anti-bacterial effects may be bacteriocidal or bacteriostatic in nature, although the former is preferred.
  • the existence of anti-bacterial activity may be ascertained by comparing the level of metabolically active or live bacteria in the test sample to control samples. This assessment may be achieved by any appropriate technique which identifies metabolic activity. Thus for example, transcriptional or translational activity may be assessed in respect of one or more genes, e.g. by monitoring gene transcript levels, or more generally, e.g. by monitoring the incorporation of particular bases or amino acids. Alternatively other techniques may be used, e.g. the ability to form colonies may be assessed, e.g. cfu counts may be determined after resuscitation in liquid culture even though direct plating on solid media without intermediate liquid medium culture may fail to yield cfu. Compounds of interest may optionally be re-screened at different concentrations, for example to establish the MIC level.
  • Compounds or agents having anti-bacterial activity are considered to be those which, at the concentration used, adversely affect the metabolic activity of the phenotypically antibiotic-resistant subpopulation, preferably by reducing metabolic activity to less than 50%, especially preferably less than 25%, e.g. less than 10% compared to untreated control samples.
  • Candidate compounds identified in such a manner for example exhibiting a minimum inhibitory concentration of 10 ⁇ g/ml or less, preferably 1 ⁇ g/ml or less, especially preferably 0.1 ⁇ g/ml (as assessed with bacteria at a concentration of 10 6 to 10 7 cfu/ml) in respect of the resistant subpopulation, may then be subjected to further analysis, efficacy and toxicity tests etc.
  • kits for performing the screening method of the invention comprising at least the following:
  • the kit also contains appropriate buffers and solutions (particularly for maintaining the bacteria, e.g. including appropriate antibacterial agents) for assessing antibacterial effects of the test compound or agent by ascertaining metabolic activity of the bacteria.
  • the kit may also include means for standardization of the assay or for comparative purposes.
  • test compounds or antibacterial agents identified or isolated by the above mentioned process are preferably produced on a larger scale for further testing or use. Depending on the nature of the test compounds this may be achieved using synthetic or natural processes or a combination of both. For example, where the test compound is a peptide this may be produced synthetically by peptide synthesis or may be produced by expression of an appropriate DNA molecule.
  • the present invention provides a process for preparing an agent having anti-bacterial activity against stationary phase bacteria wherein said agent identified according to the process described herein is amplified.
  • the present invention is directed towards novel chemical compounds which exhibit bacteriostatic or bactericidal effects on an antibacterial agent resistant subpopulation of stationary phase bacteria, e.g. a rifampicin-resistant subpopulation of M. tuberculosis , a kanamycin-resistant subpopulation of E. coli or an ampicillin-resistant subpopulation of S. aureus .
  • the present invention provides antibacterial agents identified by the above described process.
  • Anti-bacterial agents identified according to the invention have particular utility in the treatment of diseases or disorders in which dormant bacteria provide a pool from which symptomatic disease may be initiated or restarted.
  • diseases resulting from pathogenic bacteria of the genera Staphylococcus, Escherichia, Hemophilus and Mycobacterium may be targetted.
  • Anti-bacterial agents having activity against the persistent bacteria may be used during symptomatic or asymptomatic stages of the disease or condition, when those persistent bacteria are dormant or in a non-dormant state, and optionally may be used in conjunction with agents directed to non-dormant bacteria.
  • “Non-dormant bacteria” as used herein includes bacteria which at the time are in a non-dormant state, ie. are actively growing, but may or may not at other times exhibit a dormant state.
  • the present invention is directed towards a composition or formulation comprising a novel antimicrobial e.g. antibacterial agent or chemical compound as described herein and a pharmaceutically acceptable diluent or excipient.
  • a novel antimicrobial e.g. antibacterial agent or chemical compound as described herein and a pharmaceutically acceptable diluent or excipient.
  • compositions are pharmaceutically acceptable.
  • pharmaceutically acceptable is meant that the ingredient must be compatible with other ingredients of the compositions as well as physiologically acceptable to the recipient.
  • compositions according to the invention may be formulated in conventional manner using readily available ingredients.
  • the active ingredient may be incorporated, optionally together with other active substances, with one or more conventional carriers, diluents and/or excipients, to produce conventional galenic preparations such as tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders, and the like.
  • Example of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, manitol, starches, gum acacia, calcium phosphate, aglinates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, water, water/ethanol, water/glycol, water/polyethylene glycol, propylene glycol, methyl cellulose, methylhydroxybenzoates, propyl hydroxybenzoates, talc, magnesium stearate, mineral oil or fatty substances such as hard fat or suitable mixture thereof.
  • tuberculosis and other disease states where the establishment and existence of dormant bacteria is problematic it may be advantageous to administer a combination of antibacterial agents which are respectively directed towards the different growth phases of these organisms.
  • an appropriate chemotherapeutic approach to the treatment of tuberculosis and similar diseases would be to administer to a patient one or more antibacterial agents directed against the growing or log-phase of the microorganisms and one or more antibacterial agents directed against the dormant or stationary phase population.
  • a preferred formulation according to the present invention comprises at least one antibacterial agent which has activity against actively growing bacteria and at least one antibacterial agent or chemical compound (as described herein) having activity against the phenotypically resistant subpopulation of the stationary phase of said bacteria.
  • Such formulations may be presented as a combined preparation for simultaneous, separate or sequential use in the treatment of bacterial infections such as tuberculosis.
  • Such formulations may be administered during symptomatic or asymptomatic stages of the disease, ie. the antibacterial agent against the resistant sub-population need not necessarily be used when these bacteria are in the dormant phase but may be used when they are actively growing.
  • antibacterial agents which have activity against actively growing bacteria exhibit antibacterial effects as described hereinbefore against bacteria during the log-phase.
  • the present invention provides the compounds or agents, identified as effective against phenotypically resistant subpopulations of stationary phase bacteria, e.g. by the above described screening process, or compositions containing them for use in the treatment of bacterial infection.
  • bacterial infections which may appropriately be treated are those in which persistent bacteria would remain after infection even when the infected macroorganism is asymptomatic, e.g. before the onset of disease or after treatment with known antibacterials.
  • bacteria may be in the dormant phase and thus in a preferred aspect the bacterial infection to be treated involves (or could potentially involve) dormant bacteria, insofar as the infection is typified or characterized by a subpopulation of persistent bacteria which remain in asymptomatic patients in the absence of actively growing bacteria, ie. which may enter a dormant phase after infection.
  • the present invention relates to the use of compounds or agents identified as effective against phenotypically resistant subpopulations of stationary phase bacteria, e.g. by the above screening process, or compositions containing them in the preparation of a medicament for the treatment of bacterial infections.
  • the present invention provides a method of treatment of a bacterial infection comprising administering to a patient in need of such therapy an effective amount of an antibacterial agent or compound directed towards the stationary phase of growth, optionally in the presence of one or more antibacterial agent directed towards the growing phase of said organism.
  • the animal to be treated is a mammal, especially preferably a human.
  • administration may be made when the diseased individual is symptomatic or asymptomatic.
  • the antibacterial agents of the invention may be identified as effective against dormant, persistent, bacteria, ie. in the stationary phase of growth, the agents of the invention may be administered when these bacteria are actively growing.
  • Administration of the composition may take place by any of the conventional routes, e.g. orally, rectally or parenterally such as by intramuscular, subcutaneous, intraperitoneal or intravenous injection.
  • the active ingredient in such compositions may comprise from about 0.01% to about 99% weight of the formulation, preferably from about 0.1 to about 50%, for example 10%.
  • the precise dosage of the active ingredient to be administered and the length of the course of treatment will, of course, depend on a number of factors including for example, the age and weight of the patient, the specific condition requiring treatment and its severity, and the route of administration.
  • the stationary phase bacteria which are the target of the antibacterial agents may include pathogenic bacteria such as Staphylococcus aureus, Haemophilus influenzae, Streptococcus pyogenes, Streptococcus gordonii, Escherichia coli and particularly preferably, Mycobacterium tuberculosis.
  • pathogenic bacteria such as Staphylococcus aureus, Haemophilus influenzae, Streptococcus pyogenes, Streptococcus gordonii, Escherichia coli and particularly preferably, Mycobacterium tuberculosis.
  • FIG. 1 shows growth curves for E. coli and S. aureus over a period of 10 days
  • FIG. 2 shows the viability of E. coli after treatment with 50 ⁇ g/ml kanamycin during stationary phase and log phase growth;
  • FIG. 3 shows the viability of S. aureus after treatment with 100 ⁇ g/ml ampicillin during stationary phase and log phase growth.
  • M. tuberculosis H37Rv was grown in Middlebrook 7H9 broth containing 0.05% Tween® 80 supplemented with 10% ADC, without agitation or other disturbance for up to 100 days, in accordance with the procedure of Wayne (1976) Amer. Rev. Resp. Dis. 114: 807-811. Where the stationary phase organisms were viable they were resistant to MIC levels of 0.1 ⁇ g/ml rifampicin.
  • Sterility of the culture was checked before further experiments. 2 ⁇ 100 ⁇ l samples of the culture was added to blood agar plates in duplicate which were incubated at 37° C. overnight. The cell suspension was kept at 4° C. overnight. Contaminated cultures should always be discarded.
  • M. tuberculosis was grown in 7H9 medium containing 0.05% of Tween® 80 supplemented with 10% ADS (Difco Laboratories) without shaking for 100 days.
  • Rifampicin was added to the cultures at a final concentration of 100 ⁇ g/ml for 5 days. Viability was estimated at one day intervals.
  • the cells were thoroughly washed and 100 ⁇ l of samples from 10-fold dilutions of the cultures were added to triplicate plates of Middlebrook 7H11 medium supplemented with OADC (Difco Laboratories). Colony forming units (CFU's) were counted after incubation of the plate for 3 weeks at 37° C. Broth counts were performed at 10-fold dilutions by adding 1 ml of the sample to 9 ml of 7H9 medium. Viability was estimated by examining growth in the diluted cultures after incubation for 6 weeks at 37° C.
  • RNA polymerase sub-unit B 16 kDa protein
  • ⁇ -crystallin homolog 16S rRNA and two Sigma 70 homologues
  • M. tuberculosis was grown in BALB/c mice weighing 18-20 g which were infected intravenously with 2 ⁇ 10 5 cfu of a mouse-passaged, virulent H37Rv strain of M. tuberculosis .
  • Spleens and lungs were removed rapidly after sacrifice and sterile autopsy at time point ⁇ 2 week and 0 week (2 weeks after infection); portions of the organs were immediately frozen in liquid N 2 .
  • Cfu counts of viable M. tuberculosis were done by grinding the spleen and lungs in 5 ml water in motor-driven polytetrafluorethylene/glass grinders and setting up counts from serial dilution of the homogenate on plates of selective 7H11 medium (Difco, Detroit).
  • mice were then given for 14 weeks with 1000 mg pyrazinamide/kg and 25 mg isoniazid/kg body weight in the pelleted diet when the “sterile state” was reached.
  • a sample of mice was also sacrificed at the 7 week timepoint.
  • a further sample was then sacrificed at timepoint 14, and the entire organ homogenates were cultured in selective Kirchner liquid medium (Lab M, Amersham). Culture media were made selective for M. tuberculosis by the addition of 200 U polymyxin B/ml, 100 ⁇ g carbenicillin/ml, 20 ⁇ g trimethoprim/ml and 10 ⁇ g amphotericin/ml.
  • the remaining sample of mice were administered steroid therapy.
  • RT-PCR of RNA from lungs removed before treatment revealed transcripts for rpoB, sigA, sigB, 16K and 16S rRNA.
  • bacterial mRNA for sigB and 16K was detected in lungs from day 91 (13 weeks) post treatment and the level of 16S rRNA was not reduced compared to the pre-chemotherapy level. It is surprising to find any mRNA at all after 13 weeks of chemotherapy since mRNA is depleted within a few hours.
  • we were not able to measure the half-life of mRNA in vivo or the uptake of [ 3 H] -uridine into RNA we could not discriminate between unstable and stable mRNAs. Nevertheless, the data suggest that, substantial numbers of persisting bacilli are present in the lungs at day 91 which may be metabolically active because they contain mRNA, but are not culturable. All lungs used for RT-PCR were culture negative.
  • the sigA transcripts were not detectable in mouse persisters and this may be due to low abundance of this mRNA leading to levels below detectable limits, or it could be due to insensitive primers. Current data do not discriminate between these possibilities.
  • the sigF transcripts (data not shown) were detected in the Cornell mice but the bands were very weak. All controls were performed to ensure RT-PCR products derived from mRNA and not from contaminating genomic DNA.
  • mice Two weeks after infection, at time 0 week, a sample of 4 mice yielded 2-5 ⁇ 10 7 cfu/lungs or spleen. Four further mice were sacrificed at 7 and 14 weeks. of these 8 mice two yielded a positive organ culture, one from the spleen only and one from the lungs. However, mice in this “sterile” state contain large amounts of M. tuberculosis DNA which is estimated to be equivalent to 10 5 bacteria per organ. Upon treatment of the mice with steroids, spleens and lungs yielded positive cultures indicating reactivation from a dormant, non-culturable and drug insensitive state.
  • a series of 10-fold dilutions of the samples may be required, which is made in 7H9 broth with 0.05% Tween 80 but without ADC, then the diluted samples are plated on 7H11 agars and the concentration effect of the candidate compounds determined.
  • Escherichia coli K12 and Staphylococcus aureus are grown in 10 ml of nutrient broth No. 2 (Oxoid) with continuous shaking at 120 rpm for 10 days. viability of the bacteria is estimated by colony forming unit counts at 2 hours intervals for the first 24 hours and 12-24 hours afterward. From serial 10-fold dilutions of the experimental cultures, 100 ⁇ l samples are added to triplicate plates of nutrient agar plates (Oxoid). Colony forming units (CFU) are counted after incubation of the plates at 37° C. for 24 hours.
  • CFU Colony forming units
  • FIG. 1 The effect of antibiotic exposure on the E. coli and S. aureus during both log and stationary phase of growth is shown in FIGS. 2 and 3. Treatment of the cultures during stationary phase results in the selection of an antibiotic resistant subpopulation of cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
US09/842,637 1998-11-09 2001-04-27 Screening process for antibacterial agents Abandoned US20020031819A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/842,637 US20020031819A1 (en) 1998-11-09 2001-04-27 Screening process for antibacterial agents
US10/919,354 US20050019892A1 (en) 1998-11-09 2004-08-17 Screening process for antibacterial agents
US12/343,176 US7892782B2 (en) 1998-11-09 2008-12-23 Screening process for antibacterial agents

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10765598P 1998-11-09 1998-11-09
GBGB9824553.3A GB9824553D0 (en) 1998-11-09 1998-11-09 Improvements in or relating to screening antibacterial agents
GB9824553.3 1998-11-09
GB9909962.4 1999-04-29
GBGB9909962.4A GB9909962D0 (en) 1999-04-29 1999-04-29 Improvemments in or relating to screening antibacterial agents
PCT/GB1999/003728 WO2000028074A1 (en) 1998-11-09 1999-11-09 Screening process for antibacterial agents
US09/842,637 US20020031819A1 (en) 1998-11-09 2001-04-27 Screening process for antibacterial agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/003728 Continuation WO2000028074A1 (en) 1998-11-09 1999-11-09 Screening process for antibacterial agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/919,354 Continuation US20050019892A1 (en) 1998-11-09 2004-08-17 Screening process for antibacterial agents

Publications (1)

Publication Number Publication Date
US20020031819A1 true US20020031819A1 (en) 2002-03-14

Family

ID=27269546

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/842,637 Abandoned US20020031819A1 (en) 1998-11-09 2001-04-27 Screening process for antibacterial agents
US10/919,354 Abandoned US20050019892A1 (en) 1998-11-09 2004-08-17 Screening process for antibacterial agents
US12/343,176 Expired - Fee Related US7892782B2 (en) 1998-11-09 2008-12-23 Screening process for antibacterial agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/919,354 Abandoned US20050019892A1 (en) 1998-11-09 2004-08-17 Screening process for antibacterial agents
US12/343,176 Expired - Fee Related US7892782B2 (en) 1998-11-09 2008-12-23 Screening process for antibacterial agents

Country Status (10)

Country Link
US (3) US20020031819A1 (da)
EP (1) EP1129212B1 (da)
JP (1) JP3737365B2 (da)
AT (1) ATE272717T1 (da)
AU (1) AU1061100A (da)
DE (1) DE69919196T2 (da)
DK (1) DK1129212T3 (da)
ES (1) ES2229780T3 (da)
PT (1) PT1129212E (da)
WO (1) WO2000028074A1 (da)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077805B2 (en) 2014-12-05 2024-09-03 Ip Specialists Ltd. Laser-scatter measurement instrument for organism detection and related network
US12447468B2 (en) 2013-12-06 2025-10-21 Ip Specialists Ltd. Cuvette assembly having chambers for containing samples to be evaluated through optical measurement

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982153B1 (en) * 1998-12-03 2006-01-03 Targanta Therapeutics, Inc. DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US20080220465A1 (en) * 2007-03-05 2008-09-11 Pocared Diagnostics, Inc. Antibiotic Sensitivity Testing Method
HUE041512T2 (hu) 2010-03-30 2019-05-28 Helperby Therapeutics Ltd Új kombináció és alkalmazás
US20130149701A1 (en) * 2010-06-17 2013-06-13 Ying Zhang Methods of identifying therapeutic agents for treating persister and bacterial infection
WO2012017215A1 (en) 2010-08-05 2012-02-09 Helperby Therapeutics Limited Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine
GB201013207D0 (en) 2010-08-05 2010-09-22 Helperby Therapeutics Ltd Novel combination
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
GB201305277D0 (en) 2013-03-22 2013-05-01 Helperby Therapeutics Ltd Novel combination and use
GB201307989D0 (en) 2013-05-02 2013-06-12 Helperby Therapeutics Ltd Novel combinations and use
GB201401617D0 (en) 2014-01-30 2014-03-19 Helperby Therapeutics Ltd Novel combination and use
DK3233105T3 (da) 2014-12-18 2020-11-16 Helperby Therapeutics Ltd Hidtil ukendt kombination og anvendelse
US20180214440A1 (en) 2015-04-11 2018-08-02 Helperby Therapeutics Limited Oral composition
GB201518969D0 (en) 2015-10-27 2015-12-09 Helperby Therapeutics Ltd Triple combination
GB201521771D0 (en) 2015-12-10 2016-01-27 Helperby Therapeutics Ltd Formulation
GB201610869D0 (en) 2016-06-22 2016-08-03 Helperby Therapeutics Ltd Combination
GB201612093D0 (en) 2016-07-12 2016-08-24 Helperby Therapeutics Ltd Combination
GB201616014D0 (en) 2016-09-20 2016-11-02 Helperby Therapeutics Ltd Combination
GB201616909D0 (en) 2016-10-05 2016-11-16 Helperby Therapeutics Ltd Combination
GB201703898D0 (en) 2017-03-10 2017-04-26 Helperby Therapeautics Ltd Method
GB201704620D0 (en) 2017-03-23 2017-05-10 Helperby Therapeautics Ltd Combinations
GB201709193D0 (en) 2017-06-09 2017-07-26 Helperby Therapeutics Ltd Combination
GB201807046D0 (en) 2018-04-30 2018-06-13 Helperby Therapeutics Ltd Combination
GB2589286A (en) * 2019-07-22 2021-06-02 Helperby Therapeutics Ltd Method
GB201913068D0 (en) 2019-09-10 2019-10-23 Helperby Therapeutics Ltd Combination
GB201914847D0 (en) 2019-10-14 2019-11-27 Helperby Therapeutics Ltd Combination
GB202213753D0 (en) 2022-09-20 2022-11-02 Helperby Therapeutics Ltd Antimicrobial combinations
GB202213750D0 (en) 2022-09-20 2022-11-02 Helperby Therapeutics Ltd Antimicrobial
GB202314387D0 (en) 2023-09-20 2023-11-01 Helperby Therapeutics Ltd Antimicrobial combinations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697648A (en) * 1968-05-24 1972-10-10 Meiji Seika Ltd Kk Antibiotic sf-767-a and sf767-l substances,and process for producing same culturing a certain streptomyces microsporeus
US3963576A (en) * 1975-02-21 1976-06-15 General Environmental Science Corporation Method for rendering bacteria dormant and the product produced thereby
US4234579A (en) * 1977-06-07 1980-11-18 Pfizer Inc. Penicillanic acid 1,1-dioxides as β-lactamase inhibitors
US5670350A (en) * 1990-08-20 1997-09-23 Novartis Finance Corporation Genomic DNA encoding a pseudomonas global transcriptional activation element and its use in activating gene expression
US5684144A (en) * 1993-07-28 1997-11-04 University Of North Texas Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US5712095A (en) * 1994-06-16 1998-01-27 Becton Dickinson And Company Rapid and sensitive detection of antibiotic-resistant mycobacteria using oligonucleotide probes specific for ribosomal RNA precursors
US5733774A (en) * 1995-02-02 1998-03-31 Ecoscience Corporation Method and composition for producing stable bacteria and bacterial formulations
US5700925A (en) * 1996-03-27 1997-12-23 The Johns Hopkins University DNA encoding stationary phase, stress response sigma factor from Mycobacterium tuberculosis
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US5963576A (en) * 1997-08-04 1999-10-05 Motorola, Inc. Annular waveguide vertical cavity surface emitting laser and method of fabrication

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12447468B2 (en) 2013-12-06 2025-10-21 Ip Specialists Ltd. Cuvette assembly having chambers for containing samples to be evaluated through optical measurement
US12077805B2 (en) 2014-12-05 2024-09-03 Ip Specialists Ltd. Laser-scatter measurement instrument for organism detection and related network

Also Published As

Publication number Publication date
EP1129212A1 (en) 2001-09-05
DE69919196T2 (de) 2005-08-04
WO2000028074A1 (en) 2000-05-18
EP1129212B1 (en) 2004-08-04
DE69919196D1 (de) 2004-09-09
ATE272717T1 (de) 2004-08-15
JP2002529103A (ja) 2002-09-10
ES2229780T3 (es) 2005-04-16
US7892782B2 (en) 2011-02-22
US20050019892A1 (en) 2005-01-27
US20090104651A1 (en) 2009-04-23
DK1129212T3 (da) 2004-11-22
PT1129212E (pt) 2004-11-30
AU1061100A (en) 2000-05-29
JP3737365B2 (ja) 2006-01-18

Similar Documents

Publication Publication Date Title
US7892782B2 (en) Screening process for antibacterial agents
Olivier et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease
Köhler et al. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa
Blanchard Molecular mechanisms of drug resistance in Mycobacterium tuberculosis
US6346391B1 (en) Methods of reducing microbial resistance to drugs
Cohen et al. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction
Brisson-Noël et al. Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples
Chow et al. Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB (ompF) acrA] Escherichia coli K-12
WO2006029248A2 (en) Hollow fiber technique for in vivo study of cell populations
CN111096969A (zh) sutezolid(PNU-100480)在鸟分枝杆菌复合群感染中的应用
Gangadharam et al. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis: 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS
Fujita et al. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial
Bedard et al. Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin
US9427468B2 (en) Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus
Allen Nonclassical targets for antibacterial agents
JP2025534753A (ja) 健康を改善するための化合物および方法
Moustafa et al. Phenotypic detection of efflux mechanism in panaminoglycoside resistant Acinetobacter baumannii from Egyptian clinical isolates
Lienard et al. Escherichia coli Isolated from Diabetic Foot Osteomyelitis: Clonal Diversity, Resistance Profile, Virulence Potential, and Genome Adaptation. Microorganisms 2021, 9, 380
Singh et al. Exploring the Genetic and Morphological Basis of Biofilm-Linked Drug Resistance in Clinical Isolates of Acinetobacter baumannii
Yanagisawa et al. Studies of the streptomycin-resistance developed in tubercle bacilli (BCG)
AU2006200968B2 (en) Methods of reducing microbial resistance to drugs
Smith et al. THE ACTION OF TRIMETHOPRIM–SULPHAMETHOXAZOLE AGAINST URINARY PATHOGENS
Lang Atteyet-Alla Fetouh Yassin 2
Rodriguez et al. Vancomycin-Resistant Lactobacillus casei
Severin et al. Q uinolone resistance mechanisms in commensal Escherichia coliisolated in a population-based survey in Indonesia

Legal Events

Date Code Title Description
AS Assignment

Owner name: ST. GEORGES'S ENTERPRISES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COATES, ANTHONY R.M.;HU, YANMIN;REEL/FRAME:012179/0343

Effective date: 20010806

AS Assignment

Owner name: HELPERBY THERAPEUTICS LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ST.GEORGES'S ENTERPRISES LTD.;REEL/FRAME:015387/0458

Effective date: 20030306

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION